35.21
35.21 (0%)
As of Feb 14, 2025
Crinetics Pharmaceuticals, Inc. [CRNX]
Source:
Company Overview
Crinetics Pharmaceuticals, Inc is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Endocrine pathways function to maintain homeostasis and commonly use peptide hormones acting through G protein coupled receptors, or GPCRs, to regulate many aspects of physiology, including growth, energy, metabolism, gastrointestinal function and stress responses.
| Country | United States |
| Headquarters | san diego, california |
| Phone Number | (858) 450-6464 |
| Industry | manufacturing |
| CEO | R. Scott Struthers, Ph.D. |
| Website | www.crinetics.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $1 |
| Operating Profit | $-338.9 |
| Net Income | $-298.4 |
| Net Cash | $209.6 |
Profit Ratios
| Gross Margin | $1 |
| Operating Margin | -32,613.5 |
| Profit as % of Revenues | -0.4% |
| Profit as % of Assets | -28.8% |
| Profit as % of Stockholder Equity | -22.5% |
Management Effectiveness
| Return on Equity | -22.5% |
| Return on Assets | -20.8% |
| Turnover Ratio | 0.1% |
| EBITA | $-338.9 |
Balance Sheet and Cash Flow Measures
| Total Assets | $1,434.6 |
| Total Liabilities | $109.8 |
| Operating Cash Flow | $-226 |
| Investing Cash Flow | $-574.8 |
| Financing Cash Flow | $1,010.4 |
